Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $604.8M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| TPW | Ann: Change in substantial holding | 20/04/18 | 0 | 79 | |||
|
|||||||
| TPW | Ann: Appendix 4C - quarterly | 08:46 | 0 | 107 | |||
|
|||||||
| TPW | Ann: Change in substantial holding | 09/04/18 | 0 | 141 | |||
|
|||||||
| TPW | Ann: Change of Director's Interest Notice | 20/03/18 | 0 | 110 | |||
|
|||||||
| TPW | Ann: Change of Director's Interest Notice | 27/02/18 | 0 | 117 | |||
|
|||||||
See All Discussions
ASX News